Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rivalry Intensifies In Europe For Biotech Funding, Product Development

This article was originally published in The Pink Sheet Daily

Executive Summary

U.K. biotech companies lead Europe in terms of funds raised and products in development in the first half of 2014, but other countries in the region are not far behind.

You may also be interested in...



European Notebook: Accelerated Ebola Reviews; EMA Remains In Health Directorate; Ireland’s Patent Box

EMA expert group will advise Ebola developers and agency will accept rolling submissions; Irish aims to lure research-based firms with patent box, while Swedish pharma stakeholders call for investments and policy changes to bring back innovative companies.

Adaptive Licensing: Industry On Board, With Caveats

The EU's adaptive licensing pilot project, which was launched in March 2014, is designed to deliver an early centralized marketing license for promising innovative therapies for patients with serious or life-threatening conditions. However, while the benefits are clear, there are a number of challenges that will need to be addressed.

Financings Of The Fortnight And The Never-Ending Venture Round

While not as high-profile as some other venture raises over the last year, Novimmune has pulled in CHF 200.5 million in Series B financing over 16 years. Plus, news on raises by Pronutria, Melinta, Argos and Arrowhead.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel